George Sandusky

Professor

Indiana University-Purdue University Indianapolis
Country flagUnited States
ApplyKite TwinLearns as you apply

Make your next move.

Prepare your application

Review drafts before you send them.

Explore related searches

Articles (27)

Table S2: Gene expression differences between mature luminal and luminal progenitor cells of the breast. Data are from 15 samples, five each from women of European, African and Latina ancestry.

Year:

2025

Table S8: Multivariable analysis for overall (N=469) and progression-free (N=453) survival NOT including HER2. Overall and Progression-Free survival data of patients with ER+ breast cancer and treated with endocrine therapy are also shown.

Year:

2025

Table S15: List of genes differentially expressed upon TONSL overexpression in primary cells with genes differentially expressed in TMD-436 upon TONSL knockdown. Fold changes in gene expression are indicated.

Year:

2025

Table S13: Enrichment of binding sites for NF-kB and p53 in chromatin regions that become accessible or closed, respectively, upon TONSL overexpression. Genes names and chromatin positions are indicated.

Year:

2025

DNA methyltransferase (DNMT) and PARP inhibitors induce a stimulator of IFN gene–dependent pathogen mimicry response (PMR) in ovarian and other cancers. In this study, we showed that combining DNMT and PARP inhibitors upregulates expression of the nucleic acid sensor NFX1-type zinc finger–containing 1 (ZNFX1) protein. ZNFX1 mediated the induction of PMR in mitochondria, serving as a gateway for stimulator of IFN gene–dependent IFN/inflammasome signaling. Loss of ZNFX1 in ovarian cancer cells promoted proliferation and spheroid formation in vitro and tumor growth in vivo . In patient ovarian cancer databases, expression of ZNFX1 was elevated in advanced stage disease, and ZNFX1 expression alone significantly correlated with an increase in overall survival in a phase III trial for patients with therapy-resistant ovarian cancer receiving bevacizumab in combination with chemotherapy. RNA sequencing revealed an association between inflammasome signaling through ZNFX1 and abnormal vasculogenesis. Together, this study identified that ZNFX1 is a tumor suppressor that controls PMR signaling through mitochondria and may serve as a biomarker to facilitate personalized therapy in patients with ovarian cancer. Significance: DNMT and PARP inhibitors induce a nucleic acid sensor, ZNFX1, that serves as a mitochondrial gateway to STING-dependent inflammasome signaling with tumor suppressor properties in ovarian cancer.

Year:

2025

Purpose: Plexiform neurofibromas (PNF) are peripheral nerve sheath tumors that cause significant morbidity in persons with neurofibromatosis type 1 (NF1), yet treatment options remain limited. To identify novel therapeutic targets for PNF, we applied an integrated multi-omic approach to quantitatively profile kinome enrichment in a mouse model that has predicted therapeutic responses in clinical trials for NF1-associated PNF with high fidelity. Experimental Design: Utilizing RNA sequencing combined with chemical proteomic profiling of the functionally enriched kinome using multiplexed inhibitor beads coupled with mass spectrometry, we identified molecular signatures predictive of response to CDK4/6 and RAS/MAPK pathway inhibition in PNF. Informed by these results, we evaluated the efficacy of the CDK4/6 inhibitor, abemaciclib, and the ERK1/2 inhibitor, LY3214996, alone and in combination in reducing PNF tumor burden in Nf1 flox/flox ;PostnCre mice. Results: Converging signatures of CDK4/6 and RAS/MAPK pathway activation were identified within the transcriptome and kinome that were conserved in both murine and human PNF. We observed robust additivity of the CDK4/6 inhibitor, abemaciclib, in combination with the ERK1/2 inhibitor, LY3214996, in murine and human NF1(Nf1) mutant Schwann cells. Consistent with these findings, the combination of abemaciclib (CDK4/6i) and LY3214996 (ERK1/2i) synergized to suppress molecular signatures of MAPK activation and exhibited enhanced anti-tumor activity in Nf1 flox/flox ;PostnCre mice in vivo . Conclusion: These findings provide rationale for the clinical translation of CDK4/6 inhibitors alone and in combination with therapies targeting the RAS/MAPK pathway for the treatment of PNF and other peripheral nerve sheath tumors in persons with NF1.

Year:

2024

Purpose: Plexiform neurofibromas (PNF) are peripheral nerve sheath tumors that cause significant morbidity in persons with neurofibromatosis type 1 (NF1), yet treatment options remain limited. To identify novel therapeutic targets for PNF, we applied an integrated multi-omic approach to quantitatively profile kinome enrichment in a mouse model that has predicted therapeutic responses in clinical trials for NF1-associated PNF with high fidelity. Experimental Design: Utilizing RNA sequencing combined with chemical proteomic profiling of the functionally enriched kinome using multiplexed inhibitor beads coupled with mass spectrometry, we identified molecular signatures predictive of response to CDK4/6 and RAS/MAPK pathway inhibition in PNF. Informed by these results, we evaluated the efficacy of the CDK4/6 inhibitor, abemaciclib, and the ERK1/2 inhibitor, LY3214996, alone and in combination in reducing PNF tumor burden in Nf1 flox/flox ;PostnCre mice. Results: Converging signatures of CDK4/6 and RAS/MAPK pathway activation were identified within the transcriptome and kinome that were conserved in both murine and human PNF. We observed robust additivity of the CDK4/6 inhibitor, abemaciclib, in combination with the ERK1/2 inhibitor, LY3214996, in murine and human NF1(Nf1) mutant Schwann cells. Consistent with these findings, the combination of abemaciclib (CDK4/6i) and LY3214996 (ERK1/2i) synergized to suppress molecular signatures of MAPK activation and exhibited enhanced antitumor activity in Nf1 flox/flox ;PostnCre mice in vivo . Conclusions: These findings provide rationale for the clinical translation of CDK4/6 inhibitors alone and in combination with therapies targeting the RAS/MAPK pathway for the treatment of PNF and other peripheral nerve sheath tumors in persons with NF1.

Year:

2024

Immortalized BRCA1- or BRCA2-mutant cells display elevated NFκB activity. A, PIK3CA H1047R distinctly influences differentiation properties of immortalized BRCA1 and BRCA2 mutation carriers. Vector control or PIK3CA H1047R -expressing breast epithelial cell lines from non-carriers (KTB34 and KTB39) and BRCA1 or BRCA2 mutation carriers were stained with indicated antibodies and characterized by flow cytometry ( n = 3). Representative data are shown. PIK3CA H1047R robustly increased EpCAM expression and increased differentiated phenotype of BRCA1-mutant cells. CD49f + /EpCAM + cells increased from 12% to 36% whereas CD49f + /EpCAM − cells decreased from 80% to 34% upon PIK3CA H1047R overexpression. B, BRCA1 mutant cells display elevated phosphorylation of p65, a NFκB subunit, which indirectly suggests activation of NFκB. Expression levels of PIK3CA in cells transduced with PIK3CA-mutant virus are shown. Regular growth media condition had to be used to detect PIK3CA-mutant overexpression because of robust induction of endogenous PIK3CA upon serum starvation. An antibody that preferentially recognizes PIK3CA H1047R mutant was used in the Western blot analysis. The same extract was used to measure pAKT(S473) and AKT to ensure that PIK3CA H1047R is functional in transduced cells. C, Approximately 30% of breast cancers in BRCA1 or BRCA2 mutation carriers carry PIK3CA mutations. Data were generated using cBioportal ( 54 ). D, Immortalized BRCA1 or BRCA2 mutant cells but not cells from non-carriers are sensitive to DMAPT. PIK3CA H1047R -overexpressing cells, irrespective of BRCA mutation status, were sensitive to DMAPT (statistical test used—one-way ANOVA). E, Immortalized cell lines from BRCA1 or BRCA2 mutation carriers express higher levels of MIR205HG (statistical test used—unpaired t test). Note that PIK3CA H1047R , which robustly induced differentiation of BRCA1-mutant cells, reduced MIR205HG levels in these cells. P values, *

Year:

2024

Expression levels of previously described BL-enriched genes as well as those described to be enriched in breast epithelial cells of BRCA1 mutation carriers. A, Expression patterns of specific genes in cells from BRCA1 mutation carrier compared with non-carriers. Alveolar progenitor (AP) cell–enriched and BL cell–enriched genes are indicated. KIT expression is shown to mark LASP cells. Note a unique subpopulation within LASP cells that express higher levels of ALDH1A3 in BRCA1 mutation carriers. CALML5 and FAM3B are AP-enriched whereas SCGB2A2 and FXYD5 are BL-enriched genes. B, Expression patterns of specific genes in cells from BRCA2 mutation carriers compared with non-carriers.

Year:

2024

Comparison of breast epithelial cells of BRCA1 and BRCA2 mutation carriers with that of non-carriers. Breast epithelial cells were subclassified into BM, LASP, and LHS cells based on CD49f and EpCAM expression status as described previously ( 10 ). A, Side-by-side comparison of breast epithelial cells of BRCA1 mutation carriers with that of non-carriers. A distinct cluster of LASP cells is present only in non-carriers (indicated by an oval shape). B, Side-by-side comparison of breast epithelial cells of BRCA2 with that of non-carriers. Similar to BRCA1, a distinct cluster of LASP cells is present only in non-carriers. C, Side-by-side comparison of breast epithelial cells from BRCA1 mutation carriers with that of BRCA2 mutation carriers. D, Distribution pattern of BM, LASP, and LHS cells in non-carrier, BRCA1 and BRCA2 mutation carriers. E, Heat map showing top 10 genes highly expressed in cluster missing in BRCA1 and BRCA2 mutation carriers compared with other clusters.

Year:

2024

Year:

2024

Year:

2024

Year:

2024

Year:

2024

Year:

2024

Year:

2024

Year:

2024

Year:

2024

Year:

2024

Year:

2024

Year:

2024

Year:

2024

Year:

2024

Year:

2024

Year:

2024

Year:

2024

Year:

2024

Collaborators (18)

Rachel Abbotts

Assistant Professor

West Virginia University

UNITED STATES
View details

Sandro Santagata

Brigham and Women's Hospital

UNITED STATES
View details

Yue Wang

Indiana University School of Medicine

UNITED STATES
View details

Greg Donoho

Chief Galactic Overlord

-

UNITED STATES
View details

Jun Wan

Associate Professor

Indiana University-Purdue University Indianapolis

UNITED STATES
View details

Xiaoling Xuei

Research professor

Indiana University School of Medicine

UNITED STATES
View details

Vijay Tiwari

The Queen's University Belfast

UNITED KINGDOM
View details

Douglas Wallace

Professor

University of Pennsylvania

UNITED STATES
View details

Kenneth P Nephew

Professor

Indiana University

UNITED STATES
View details

Steven Angus

Assistant Professor

Indiana State University

UNITED STATES
View details

Chi Zhang

Associate Professor

Oregon Health & Science University

UNITED STATES
View details

Harikrishna Nakshatri

Professor

Indiana State University

UNITED STATES
View details

Yunlong Liu

Professor

Indiana State University

UNITED STATES
View details

Jean-Pierre J Issa

Coriell Institute For Medical Research

UNITED STATES
View details

Tanjina Kader

Lab Head/Senior Lecturer

MONASH UNIVERSITY

AUSTRALIA
View details

Kathy Miller

Indiana University Bloomington

UNITED STATES
View details

Ronny Drapkin

Franklin Payne Professor of Pathology in Obstetrics and Gynecology

University of Pennsylvania

UNITED STATES
View details

Boris Winterhoff

Associate Professor

University of Minnesota

UNITED STATES
View details